Long Term Infection Prevention Demand Will Drive Expanding Cash Generation And Durable Market Leadership

Catalysts

About CorMedix

CorMedix develops and commercializes differentiated therapies that prevent and treat serious, life-threatening infections in acute care settings.

What are the underlying business or industry changes driving this perspective?

• Rapidly growing adoption of DefenCath in outpatient hemodialysis, with utilization running ahead of initial rollout expectations, supports continued double digit revenue expansion and strengthens visibility into durable cash generation.
• Rezzayo prophylaxis in immunocompromised transplant and hematologic oncology patients targets a multibillion dollar antifungal prevention market where current standards of care have drug interaction and dosing limitations. This creates potential for a new standard of care and a material second leg of revenue and earnings growth.
• Expansion of DefenCath into prevention of catheter-related infections in total parenteral nutrition patients addresses a large, highly underserved hospital and home nutrition population. This can add a sizeable incremental revenue stream while leveraging existing infrastructure to enhance net margins.
• Real world evidence demonstrating reductions in central line infections, hospitalizations and related resource use is expected to support broader payer and Medicare Advantage adoption. This may improve pricing power and help sustain attractive gross and operating margins over time.
• Faster than expected integration of the Melinta acquisition and early capture of tens of millions of dollars in annualized synergies, combined with a unified acute care salesforce, are intended to drive operating leverage and expand adjusted EBITDA and free cash flow as the portfolio scales.

Assumptions

This narrative explores a more optimistic perspective on CorMedix compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts. How have these above catalysts been quantified?

• The bullish analysts are assuming CorMedix's revenue will grow by 38.4% annually over the next 3 years.
• The bullish analysts assume that profit margins will shrink from 75.8% today to 52.6% in 3 years time.
• The bullish analysts expect earnings to reach $298.7 million (and earnings per share of $3.21) by about December 2028, up from $162.5 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as $63.3 million.
• In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 8.7x on those 2028 earnings, up from 5.7x today. This future PE is lower than the current PE for the US Pharmaceuticals industry at 19.9x.
• The bullish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 6.96%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Rezzayo prophylaxis and DefenCath TPN expansion both rely on late stage trials that will not read out until 2026 or later, and any delay, failure to show sufficient benefit versus standard of care, or safety concerns could remove major expected growth drivers and cap long term revenue and earnings expansion.
• The July 2026 transition out of TDAPA and uncertainty around the final ESRD rule or proposed legislative changes may result in greater than anticipated price compression for DefenCath, which could pressure net revenue growth and reduce net margins once initial hemodialysis momentum normalizes.
• Real world evidence is central to negotiating with Medicare Advantage and hospital customers, and if these data fail to demonstrate strong reductions in infections and hospitalizations versus historical rates, CorMedix could struggle to gain broader payer coverage and premium pricing, limiting revenue and constraining future earnings.
• The Melinta acquisition and Talphera investment increase operational complexity, integration, and systems work running into 2026 and beyond, so any failure to fully capture the projected 35 million to 45 million dollars of synergies, or unexpected integration costs, could erode the current profitability trajectory and compress operating margins and free cash flow.
• CorMedix is building its long term strategy around high cost acute care and immunocompromised populations that are sensitive to payer scrutiny and future cost containment policies, and sustained pressure from Medicare, Medicare Advantage, and hospital systems to reduce expensive prophylactic therapies could slow adoption, weigh on revenue growth, and limit earnings scalability over time.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bullish price target for CorMedix is $22.0, which represents up to two standard deviations above the consensus price target of $19.0. This valuation is based on what can be assumed as the expectations of CorMedix's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $22.0, and the most bearish reporting a price target of just $14.0.
  
• In order for you to agree with the more bullish analyst cohort, you'd need to believe that by 2028, revenues will be $567.7 million, earnings will come to $298.7 million, and it would be trading on a PE ratio of 8.7x, assuming you use a discount rate of 7.0%.
  
• Given the current share price of $11.74, the analyst price target of $22.0 is 46.6% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.